Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening TestsBusiness Wire • 08/06/25
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ TestBusiness Wire • 07/31/25
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/30/25
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?Zacks Investment Research • 07/25/25
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a BetZacks Investment Research • 07/15/25
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 PatentBusiness Wire • 07/10/25
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal CancerBusiness Wire • 07/09/25
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?Zacks Investment Research • 06/05/25
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation RoadmapBusiness Wire • 05/28/25
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025Business Wire • 05/22/25
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual GuidanceBenzinga • 05/02/25
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View RaisedZacks Investment Research • 05/02/25